OncoZenge - Report Comment: Green light to initiate Phase III

2026-05-26 15:51:00

Impala Nordic comments on OncoZenge AB (publ) ("OncoZenge" or the "Company") Q1 2026 and the receipt of full European regulatory approval to initiate the pivotal Phase III trial of BupiZenge™.

The CTA approval is one of the most important milestones in the Company's history, removes the primary near-term uncertainty, and triggers committed financing from both Yangtian Pharma and Molteni Farmaceutici amounting to approximately 21 MSEK. The spotlight now shifts decisively to first patient enrollment, recruitment pace, and ultimately trial readout.

Click here to read the comment.

About Impala Nordic

Impala Nordic provides equity research, coverage, and comprehensive investor relations (IR) services. The portfolio includes listed small-cap companies, where Impala Nordic acts as a communicative bridge between the companies and investors.

The material produced by Impala Nordic is independent but sponsored. This means that Impala Nordic has received payment from the client to produce the analysis and coverage. The client has not been able to influence Impala Nordic’s opinions expressed in the material.